Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Adaptimmune Therapeutics's operating income for the twelve months ending Jun 30, 2025 was -$164.22M. For fiscal 2024 it was -$68.76M. The highest annual figure on record is -$11.52M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$68.76M | – |
| FY2023 | Dec 31, 2023 | -$139.74M | – |
| FY2022 | Dec 31, 2022 | -$163.97M | – |
| FY2021 | Dec 31, 2021 | -$162.25M | – |
| FY2020 | Dec 31, 2020 | -$133.41M | – |
| FY2019 | Dec 31, 2019 | -$139.77M | – |
| FY2018 | Dec 31, 2018 | -$82.37M | – |
| FY2017 | Dec 31, 2017 | -$80.66M | – |
| FY2015 | Jun 30, 2015 | -$24.64M | – |
| FY2014 | Jun 30, 2014 | -$11.52M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$30.29M | -144.1% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$45.73M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$73.52M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$14.68M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $68.70M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$49.26M | -3074.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$49.86M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$46.63M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$44.91M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $1.66M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$27.24M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$42.99M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$43.75M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$49.98M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$42.86M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$42.18M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$39.31M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$37.89M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$37.51M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$35.88M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$30.25M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$29.76M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$30.36M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$40.12M | -671.7% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$35.50M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$33.79M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$32.11M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $7.02M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$28.88M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$28.74M | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$29.70M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$4.96M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$23.78M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$22.22M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$11.11M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$5.61M | – |
See a number that looks wrong?